Shares of Baxter International Inc (NYSE:BAX) ended Monday session in red amid volatile trading. The shares closed down -0.03 points or -0.06% at $47.25 with 543.89 million shares getting traded. Post opening the session at $47.36, the shares hit an intraday low of $47.12 and an intraday high of $47.78 and the price vacillated in this range throughout the day. The company has a market cap of $25.81 billion and the numbers of outstanding shares have been calculated to be 543.89 million shares.
Baxter International Inc (BAX) on September 19, 2016 announced the European launch of NUMETA G13E 300 mL, the only ready-to-use parenteral (intravenous) nutrition (PN) product available to treat preterm infants (less than 37 weeks gestation age) who are at high risk for infection and malnutrition1 in the early hours and days of their lives. The announcement was made during the 38th ESPEN (The European Society for Clinical Nutrition and Metabolism) Congress in Copenhagen, Sept. 17-20, with recognition that the first preterm patients have received PN therapy on NUMETA G13E in Sweden.
NUMETA G13E is indicated for PN administration in preterm newborn infants when oral or enteral nutrition is not possible, insufficient or contraindicated. NUMETA G13E addresses an important medical need to support preterm neonatal patients who have acute nutritional requirements by providing a balanced formulation of amino acids (protein), glucose (carbohydrates), lipids (fats) and electrolytes in a triple-chamber system that was pioneered by Baxter.
”Baxter’s NUMETA G13E is a well-balanced, ready-to-use formula in a triple-chamber system that simplifies the preparation process for healthcare workers and helps reduce the potential risk to patients of infection and dosing errors,” said Brik Eyre, president of Baxter’s Hospital Products business. ”NUMETA G13E is truly innovative nutritional therapy for preterm babies – among the most susceptible patients – when time and safety are critical factors to their care.”
Shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) ended Monday session in red amid volatile trading. The shares closed down -0.10 points or -0.48% at $20.85 with 28.84 million shares getting traded. Post opening the session at $20.90, the shares hit an intraday low of $20.84 and an intraday high of $20.95 and the price vacillated in this range throughout the day. The company has a market cap of $604.51 million and the numbers of outstanding shares have been calculated to be 28.84 million shares.
Vitae Pharmaceuticals Inc (VTAE) on Aug. 10, 2016 announced the appointment of Scott Applebaum as General Counsel and Corporate Secretary, effective immediately. Mr. Applebaum most recently served as Chief Legal Officer and Corporate Secretary at Medgenics, Inc., a genomics medicine company focused on rare pediatric diseases.
“Scott’s extensive experience in providing legal and corporate compliance guidance will be invaluable to Vitae as our pipeline of first-in-class therapies continues to grow and advance,” said Jeff Hatfield, President and Chief Executive Officer of Vitae. “We are delighted to welcome Scott to the team.”